Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687837 · ClinicalTrials.gov registry record · Phase 1
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
A Phase 1 study of Parkinson Disease, sponsored by Jeffrey S. Schweitzer, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06687837: Recruiting Phase 1 study of Parkinson Disease, sponsored by Jeffrey S. Schweitzer, MD, PhD.
NCT06687837 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by Jeffrey S. Schweitzer, MD, PhD. The registered enrollment target is 8 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06687837, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by Jeffrey S. Schweitzer, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease. The transplanted dopaminergic cells will be derived from the participant's own skin cells.
Primary Outcome
Incidence and severity of adverse events and serious adverse events
Conditions Studied
Interventions
- BIOLOGICAL autologous dopaminergic cell implantation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06687837 shows while recruiting
NCT06687837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which autologous dopaminergic cell implantation is the first listed.
NCT06687837 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06687837 about?
NCT06687837 is a clinical study titled "Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons". The goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease. The transplanted dopaminergic cells will be derived from the participant's own skin cells.
What is the current status of trial NCT06687837?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-04-29. Estimated completion is 2028-12.
What conditions does trial NCT06687837 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06687837?
The interventions under investigation include: autologous dopaminergic cell implantation (BIOLOGICAL).
Who is sponsoring clinical trial NCT06687837?
This trial is sponsored by Jeffrey S. Schweitzer, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687837 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06687837's enrollment target sits among peer trials
8 289th of 297 higher than 8 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
-
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI